News & Views
News & Views
Iksuda receives US FDA IND clearance for IKS04
CA242-directed ADC approved for assessment in Phase 1 trials in patients with GI cancers The ‘IKS04 Regimen’, is an innovative dosing approach for an ADC which is employed to overcome the challenge of solid tumour penetration for high-potency payloads
Iksuda receives US FDA IND clearance for IKS04
CA242-directed ADC approved for assessment in Phase 1 trials in patients with GI cancers The ‘IKS04 Regimen’, is an innovative dosing approach for an ADC which is employed to overcome the challenge of solid tumour penetration for high-potency payloads
Iksuda share paper via AACR
Iksuda Therapeutics are pleased to share that our paper "IKS04, a CanAg-Targeting Antibody-Drug Conjugate with Pyrrolobenzodiazepine, Shows Enhanced Efficacy with Unconjugated Antibody Coadministration in Animal Models" has been published via AACR Journals.
Iksuda to present growing ADC pipeline at AACR
Introduces the ProAlk payload series to address the growing challenge of ADC sequencing
Iksuda abstracts at AACR 2025
Iksuda’s abstracts have been scheduled for presentation in a Poster Session at the AACR Annual Meeting 2025 in Chicago, on Monday April 28 and have been published to the AACR Online Program Planner.
Iksuda deepens clinical pipeline
Iksuda Therapeutics deepens clinical pipeline through licensing agreement for Her2 antibody drug conjugate programme from LegoChem Biosciences
Licensing agreement with LegoChem Biosciences
LegoChem Biosciences and Iksuda enter Licensing Agreement for Antibody Drug Conjugate program